Novartis Annual Results

Annual Results 2019 - Jan 29, 2020

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.1 MB)

Condensed financial report (PDF 0.6 MB)

Webcasts and presentations

Media

Watch the media webcast

Download the media presentation (PDF 1.2 MB)

Investors

Watch the investor webcast

Read the presentation transcript

Download the podcast (MP3 43 MB)

Download the investor presentation (PDF 3.6 MB)

 

---

2019 Annual Reporting Suite

The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2019.

To request a hard copy of the Annual Report, fill out the order form.

Download the Annual Report 2019 (PDF 3.8 MB)

Visit the 2019 Annual Reporting Suite section

---

Form 20-F 2019

Form 20-F documents Novartis results in line with requirements of the US Securities and Exchange Commission (SEC).

English (PDF 4.0 MB)

---

XBRL package

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.7 MB)

Annual Results 2018 - Jan 30, 2019

 

Key figures1	FY 2018 (USD m)	FY 2017 (USD m)	% change (USD/cc)
Net sales	51,900	49,109	6 (cc: 5)
Operating income	8,169	8,629	-5 (cc: -5)
Net income	12,614	7,703	64 (cc: 64)
EPS (USD)	5.44	3.28	66 (cc: 66)
Free cash flow	11,717	10,428	12
Core
Operating income	13,823	12,850	8 (cc: 8)
Net income	11,938	11,391	5 (cc: 5)
EPS (USD)	5.15	4.86	6 (cc: 6)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

 

Condensed financial report (PDF 0.6 MB)

---

Read the presentation transcript

Download the podcast (MP3 51 MB)

Download the presentation (PDF 3.4 MB)

---

XBRL package

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.7 MB)

Annual Results 2016 - Jan 25, 2017

 

Continuing operations2
Key figures1	FY 2016 (USD m)	FY 2015 (USD m)	% change (USD/cc)
Net sales	48,518	49,414	-2 (cc: 0)
Operating income	8,268	8,977	-8 (cc: -3)
Net income	6,698	7,028	-5 (cc: 1)
EPS (USD)	2.82	2.92	-3 (cc: 2)
Free cash flow	9,455	9,259	2
Core
Operating income	12,987	13,790	-6 (cc: -2)
Net income	11,314	12,041	-6 (cc: -3)
EPS (USD)	4.75	5.01	-5 (cc: -2)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
2. Refers to continuing operations, defined on page 41 of the Condensed Financial Report.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.4 MB)

Français (PDF 0.4 MB)

 

Condensed financial report (PDF 0.5 MB)